Floatz logo

h3b-6545

Estrogen Receptor Positive Tumor

Eisai Inc.Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Estrogen Receptor Positive Tumor cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Gangnam Severance Hospital
Phase 4BB
Zoladex
Gangnam Severance Hospital
Phase 4BB
LEUPROLIDE
Gangnam Severance Hospital
Phase 4BB
Lipitor
Aarhus University Hospital
Phase 3B
Letrozole
ETOP IBCSG Partners Foundation
Phase 2B

View all 23 →

Same molecule, other indications

h3b-6545 is also rated in:

breast neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
ER PositiveDormant
CCC
Indicative ·
52 / 100
View asset →
breast adenocarcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →